CHA Taking Stem Cell-Based Alzheimer’s Therapy Into Clinic
This article was originally published in PharmAsia News
South Korea's CHA Biotech is set to begin the first clinical trial of a mesenchymal stem cell therapy for Alzheimer's disease, which the company plans to develop on a commercial scale by using proprietary technology that can store the cells for up to 24 months.
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.